4.7 Article

Progressive Thinning of Retinal Nerve Fiber Layer/Ganglion Cell Layer (RNFL/GCL) as Biomarker and Pharmacological Target of Diabetic Retinopathy

Journal

Publisher

MDPI
DOI: 10.3390/ijms241612672

Keywords

diabetic retinopathy; prevention; biomarker; optical coherence tomography

Ask authors/readers for more resources

Diabetes-driven retinal neurodegeneration is involved in the early stages of diabetic retinopathy, and identifying a biomarker for early retinal neurodegeneration is crucial. This study confirms that thinning of the retinal nerve fiber layer/ganglion cell layer (RNFL/GCL) precedes the death of retinal ganglion cells in a diabetic mouse model, suggesting it as a potential biomarker. Starting a neuroprotective treatment at the first sign of RNFL/GCL thinning not only prevents loss of these cells but also the development of microvascular diabetic retinopathy.
Diabetes-driven retinal neurodegeneration has recently been shown to be involved in the initial phases of diabetic retinopathy, raising the possibility of setting up a preventive strategy based on early retinal neuroprotection. To make this possible, it is crucial to identify a biomarker for early retinal neurodegeneration. To this end, in this study, we verified and confirmed that, in the Akita mouse model of diabetes, the thinning of the retinal nerve fiber layer/ganglion cell layer (the RNFL/GCL-the layer that contains the retinal ganglion cells) precedes the death of these same cells, suggesting that this dysfunction is a possible biomarker of retinal neurodegeneration. We then confirmed the validity of this assumption by starting a neuroprotective treatment (based on nerve growth factor eye drops) in concert with the first demonstration of RNFL/GCL thinning. In this way, it was possible not only to avoid the loss of retinal ganglion cells but also to prevent the subsequent development of the microvascular stage of diabetic retinopathy. In conclusion, in the case of diabetes, the thinning of the RNFL/GCL appears to be both a valid biomarker and a pharmacological target of diabetic retinopathy; it precedes the development of vascular dysfunctions and represents the ideal starting point for prevention.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available